Related Experiment Video
Updated: Jun 26, 2026

Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
Published on: March 30, 2022
Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple
L Shinto1, G Marracci, S Baldauf-Wagner
1Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA. shintol@ohsu.edu
Objectives:
The primary objective was to evaluate the effect of omega-3 fatty acids (omega-3 FA) on matrix metalloproteinase-9 (MMP-9) production by immune cells in multiple sclerosis (MS). Quality of life, fatty acid levels, and safety were also evaluated.
Materials And Methods:
Ten participants with relapsing-remitting MS (RRMS) received omega-3 FA supplementation (9.6g/day fish oil) in an open-label study. Participants were evaluated at four time points, baseline, after 1 month of omega-3 FA supplementation, after 3 months of omega-3 FA supplementation, and after a 3-month wash out.
Results:
Immune cell secretion of MMP-9 decreased by 58% after 3 months of omega-3 FA supplementation when compared with baseline levels (p<0.01). This effect was coupled with a significant increase in omega-3 FA levels in red blood cell membranes.
Conclusions:
Omega-3 FA significantly decreased MMP-9 levels in RRMS and may act as an immune-modulator that has potential therapeutic benefit in MS patients.
Insights
Omega-3 fatty acids (omega-3 FA) significantly reduced matrix metalloproteinase-9 (MMP-9) in patients with multiple sclerosis (MS). This suggests omega-3 FA may be a beneficial immune-modulator for MS treatment.
Area of Science:
- Neuroimmunology
- Nutritional Neuroscience
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Matrix metalloproteinase-9 (MMP-9) is implicated in MS pathogenesis and neuroinflammation.
Purpose of the Study:
- To investigate the impact of omega-3 fatty acids (omega-3 FA) on MMP-9 production by immune cells in relapsing-remitting MS (RRMS).
- To assess changes in quality of life, fatty acid levels, and safety associated with omega-3 FA supplementation.
Main Methods:
- An open-label study involving 10 RRMS participants.
- Supplementation with 9.6g/day of fish oil (omega-3 FA) for 3 months.
- Evaluations conducted at baseline, 1 month, 3 months, and after a 3-month washout period.
Main Results:
- A significant 58% decrease in immune cell MMP-9 secretion after 3 months of omega-3 FA supplementation (p<0.01).
- Concurrent significant increase in red blood cell membrane omega-3 FA levels.
Conclusions:
- Omega-3 FA supplementation effectively reduced MMP-9 levels in RRMS patients.
- Omega-3 FA demonstrates potential as an immune-modulating therapy for multiple sclerosis.